GlassScriptPhysician profile
Paul P Pena
NPI 1497017149
$2,622.22
in general payments reported to CMS, 2019-2025
28 companies · $666 in 2025
The $666 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $335 · 2021: $311 · 2022: $251 · 2023: $410 · 2024: $434 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,510.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $411.38 | 2019-2025 | |
| Pfizer INC. | $406.33 | 2019-2025 | |
| Amgen INC. | $330.00 | 2019-2025 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $321.53 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $204.20 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $135.72 | 2019-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $98.07 | 2019-2025 | Arexvy, Shingrix |
| Astellas Pharma US INC | $93.86 | 2019-2024 | Veozah |
| Abbott Laboratories | $76.16 | 2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $75.69 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $62.54 | 2022-2023 | Quviviq |
| Eisai INC. | $49.64 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $43.99 | 2020-2021 | |
| Esperion Therapeutics, INC. | $42.68 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $33.69 | 2023-2024 | Farxiga |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.79 | 2021-2025 | Jardiance |
| Dexcom, INC. | $26.27 | 2023 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $25.57 | 2025 | Inspire |
| Optinose US, INC. | $19.97 | 2023 | |
| Boston Scientific Corporation | $19.41 | 2023 | Watchman |
| Takeda Pharmaceuticals U.S.A., INC. | $19.01 | 2021 | |
| Scilex Pharmaceuticals INC. | $17.60 | 2023 | Ztlido |
| Amneal Pharmaceuticals LLC | $14.29 | 2020 | |
| Bausch Health US, LLC | $14.05 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.93 | 2024 | Eliquis |
| Shire North American Group INC | $12.04 | 2019 | |
| Zyla Life Sciences, INC. | $12.01 | 2019 | |
| Genentech USA, INC. | $11.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Pena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.